Literature DB >> 22579139

Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.

Jonas Bjerring Olesen1, Gregory Y H Lip, Deirdre A Lane, Lars Køber, Morten Lock Hansen, Deniz Karasoy, Carolina Malta Hansen, Gunnar Hilmar Gislason, Christian Torp-Pedersen.   

Abstract

BACKGROUND: Vascular disease (including myocardial infarction and peripheral artery disease) has been proposed as a less well-validated risk factor for stroke in patients with atrial fibrillation. We investigated whether vascular disease is an independent risk factor of stroke/thromboembolism in atrial fibrillation and whether adding vascular disease improves Congestive heart failure, Hypertension, Age 75 years, Diabetes, previous Stroke (CHADS(2)) risk stratification.
METHODS: By using nationwide Danish registers, we identified all patients discharged with atrial fibrillation and not treated with vitamin K antagonist or heparin between 1997 and 2008. The rate of stroke/thromboembolism in patients with atrial fibrillation with and without vascular disease was determined, and the risk associated with vascular disease was estimated in Cox regression analyses. The value of adding vascular disease to the CHADS(2) score was evaluated by Net Reclassification Improvement and Integrated Discrimination Improvement.
RESULTS: We included 87,202 patients with non-valvular atrial fibrillation; of these, 15,212 (17.4%) had vascular disease, 11,750 (77.2%) had myocardial infarction, 2503 (16.5%) had peripheral artery disease, and 959 (6.3%) had both. In patients with a CHADS(2) score=0, the rate of stroke/thromboembolism at 1-year follow-up was 2.31 (1.63-3.26) and 1.52 (1.34-1.73) per 100 person-years in patients with and without vascular disease, respectively. Vascular disease increased the risk of stroke/thromboembolism in both univariate (hazard ratio [HR] 1.26; confidence interval [CI], 1.18-1.35) and multivariate (HR, 1.12; CI, 1.05-1.21) analyses. The risk of stroke/thromboembolism associated with peripheral artery disease alone (HR, 1.93; CI, 1.70-2.19) was greater than the risk with myocardial infarction alone (HR, 1.12; CI, 1.04-1.21), and vascular disease significantly improved the predictive ability of the CHADS(2) score (Net Reclassification Improvement 0.032, P<.001).
CONCLUSIONS: Vascular disease is an independent predictor of stroke/thromboembolism in atrial fibrillation and improves the predictive ability of the CHADS(2) score.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22579139     DOI: 10.1016/j.amjmed.2011.11.024

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  18 in total

Review 1.  Meta-analysis of CHADS2 versus CHA2DS2-VASc for predicting stroke and thromboembolism in atrial fibrillation patients independent of anticoagulation.

Authors:  Wen-Gen Zhu; Qin-Mei Xiong; Kui Hong
Journal:  Tex Heart Inst J       Date:  2015-02-01

Review 2.  Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure.

Authors:  Christopher J Boos; Michael Nam; A J Camm
Journal:  Heart Fail Rev       Date:  2013-06-25       Impact factor: 4.214

Review 3.  Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice.

Authors:  Rohan Shah; Manesh R Patel
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-09-19

Review 4.  Atherosclerosis and Atrial Fibrillation: Double Trouble.

Authors:  Mehran Abolbashari
Journal:  Curr Cardiol Rep       Date:  2022-01-06       Impact factor: 2.931

Review 5.  Atrial fibrillation and risk of cardiovascular events and mortality in patients with symptomatic peripheral artery disease: A meta-analysis of prospective studies.

Authors:  Mislav Vrsalović; Ana Vrsalović Presečki
Journal:  Clin Cardiol       Date:  2017-12-15       Impact factor: 2.882

Review 6.  Stroke And Bleeding Risk Assessment: Where Are We Now?

Authors:  Mikhail S Dzeshka; Gregory Y H Lip
Journal:  J Atr Fibrillation       Date:  2014-04-30

7.  Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review.

Authors:  Ethan D Borre; Adam Goode; Giselle Raitz; Bimal Shah; Angela Lowenstern; Ranee Chatterjee; Lauren Sharan; Nancy M Allen LaPointe; Roshini Yapa; J Kelly Davis; Kathryn Lallinger; Robyn Schmidt; Andrzej Kosinski; Sana M Al-Khatib; Gillian D Sanders
Journal:  Thromb Haemost       Date:  2018-10-30       Impact factor: 6.681

Review 8.  Stroke and bleeding risk in atrial fibrillation.

Authors:  Keitaro Senoo; Deirdre Lane; Gregory Yh Lip
Journal:  Korean Circ J       Date:  2014-09       Impact factor: 3.243

9.  Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.

Authors:  Roger A Winkle; R Hardwin Mead; Gregory Engel; Melissa H Kong; Rob A Patrawala
Journal:  Europace       Date:  2013-09-12       Impact factor: 5.214

10.  A comparison of the CHARGE-AF and the CHA2DS2-VASc risk scores for prediction of atrial fibrillation in the Framingham Heart Study.

Authors:  Ingrid E Christophersen; Xiaoyan Yin; Martin G Larson; Steven A Lubitz; Jared W Magnani; David D McManus; Patrick T Ellinor; Emelia J Benjamin
Journal:  Am Heart J       Date:  2016-05-17       Impact factor: 4.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.